Autoantibodies to Vasoregulative [GPCRs] Correlate with Symptom Severity, Autonomic Dysfunction and Disability in ME/CFS (Freitag et al., 2021)

Pyrrhus

Senior Member
Messages
4,036
Likes
12,331
Location
U.S., Earth
Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in ME/CFS (Freitag et al., 2021)
https://doi.org/10.3390/jcm10163675

Main points:
  • This study from Carmen Scheibenbogen's group looked for correlations between certain antibodies and symptoms in ME.
  • They found that levels of most antibodies significantly correlated with key symptoms of fatigue and muscle pain in patients with infection-triggered onset, but not with patients without an infection-triggered onset.
  • Specific antibodies showed some correlation with specific symptoms.

Abstract:
Background:
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is an acquired complex disease with patients suffering from the cardinal symptoms of fatigue, post-exertional malaise (PEM), cognitive impairment, pain and autonomous dysfunction. ME/CFS is triggered by an infection in the majority of patients. Initial evidence for a potential role of natural regulatory autoantibodies (AAB) to beta-adrenergic (AdR) and muscarinic acetylcholine receptors (M-AChR) in ME/CFS patients comes from a few studies.

Methods:
Here, we analyzed the correlations of symptom severity with levels of AAB to vasoregulative AdR, AChR and Endothelin-1 type A and B (ETA/B) and Angiotensin II type 1 (AT1) receptor in a Berlin cohort of ME/CFS patients (n = 116) by ELISA. The severity of disease, symptoms and autonomic dysfunction were assessed by questionnaires.

Results:
We found levels of most AABs significantly correlated with key symptoms of fatigue and muscle pain in patients with infection-triggered onset. The severity of cognitive impairment correlated with AT1-R- and ETA-R-AAB and severity of gastrointestinal symptoms with alpha1/2-AdR-AAB. In contrast, the patients with non-infection-triggered ME/CFS showed fewer and other correlations.

Conclusion:
Correlations of specific AAB against G-protein-coupled receptors (GPCR) with symptoms provide evidence for a role of these AAB or respective receptor pathways in disease pathomechanism.
 

Pyrrhus

Senior Member
Messages
4,036
Likes
12,331
Location
U.S., Earth
Very nice results, should be perfect for BC007 right? Perhaps they should fastlane that drug.
The drug BC-007 apparently blocks all G-Protein-Coupled Receptors (GPCR) antibodies, not just the few antibodies considered in this study.

The drug BC-007 might provide temporary symptom relief for the subset of ME patients who happen to have those certain antibodies.

BC-007 is currently being tested for Long Covid and a similar study for ME has already been funded.


Related discussion:

BC-007: Successful drug against Autoantibodies helps with long COVID
https://forums.phoenixrising.me/thr...t-autoantibodies-helps-with-long-covid.84653/
 

Zebra

Senior Member
Messages
619
Likes
2,520
Location
Northern California
A comment from another thread:
You read my mind, @Pyrrhus

I was thinking, "no doctor is going to test me for these antibodies!" ... Then I saw your second post.

Thank you for letting us know these antibodies can be tested via Cell trend!

Of course, getting physicians such as neurologists and rheumatologists to take such test results seriously is a whole other topic for another thread! ;)
 

Pyrrhus

Senior Member
Messages
4,036
Likes
12,331
Location
U.S., Earth
Related discussions:

Antibodies to ß adrenergic and muscarinic cholinergic receptors in patients with CFS (2015)
https://forums.phoenixrising.me/thr...inergic-receptors-in-patients-with-cfs.40109/

Plasmapheresis study at Berlin (Charite Prof Scheibenbogen) (2016)
https://forums.phoenixrising.me/thr...y-at-berlin-charite-prof-scheibenbogen.44341/

Immunoadsorption to remove ß2 adrenergic receptor antibodies in CFS/ME (2018)
https://forums.phoenixrising.me/thr...renergic-receptor-antibodies-in-cfs-me.58277/

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption (2020)
https://forums.phoenixrising.me/thr...mmunoadsorption-published-30-july-2020.80959/